Joslin Diabetes Center Partners With Pfizer Inc. and Eli Lilly and Company to Develop Ways to Predict and Treat Kidney Failure in Type 2 Diabetes Patients
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOSTON--(BUSINESS WIRE)--Joslin Diabetes Center’s Office of Commercialization and Ventures, today announced it is collaborating with Eli Lilly and Company and Pfizer Inc. which will enable Joslin and both companies to accelerate research aimed at predicting kidney failure in patients with type 2 diabetes and developing potential ways to treat and prevent this complication of diabetes. This is the first time two pharmaceutical companies have joined forces with Joslin, the world’s leading diabetes research and clinical care organization, to identify biomarkers for predicting kidney disease. The work at Joslin has been pioneered by and will be led by Andrzej Krolewski, M.D., Ph.D., who heads Joslin’s Section on Genetics and Epidemiology.
Help employers find you! Check out all the jobs and post your resume.
BOSTON--(BUSINESS WIRE)--Joslin Diabetes Center’s Office of Commercialization and Ventures, today announced it is collaborating with Eli Lilly and Company and Pfizer Inc. which will enable Joslin and both companies to accelerate research aimed at predicting kidney failure in patients with type 2 diabetes and developing potential ways to treat and prevent this complication of diabetes. This is the first time two pharmaceutical companies have joined forces with Joslin, the world’s leading diabetes research and clinical care organization, to identify biomarkers for predicting kidney disease. The work at Joslin has been pioneered by and will be led by Andrzej Krolewski, M.D., Ph.D., who heads Joslin’s Section on Genetics and Epidemiology.
Help employers find you! Check out all the jobs and post your resume.